Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Prevenar 13™
Prevnar 13 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Prevnar 13 | ACTIVE_COMPARATOR | 13 valent Pneumococcal Conjugate |
| multivalent pneumococcal conjugate formulation 1 | EXPERIMENTAL | multivalent pneumococcal conjugate formulation 1 |
| multivalent pneumococcal conjugate formulation 2 | EXPERIMENTAL | multivalent pneumococcal conjugate formulation 2 |
| Name | Type | Description |
|---|---|---|
| Prevnar 13 | BIOLOGICAL | 13 valent Pneumococcal Conjugate |
| multivalent pneumococcal conjugate formulation 1 | BIOLOGICAL | multivalent pneumococcal conjugate formulation 1 |
| multivalent pneumococcal conjugate formulation 2 | BIOLOGICAL | multivalent pneumococcal conjugate formulation 2 |
Inclusion Criteria: * Male or female Japanese subjects 18 to 49 years of age, defined as Japanese born in Japan, with both parents and 4 grandparents who wer born in Japan (family tree by history), and who have not lived outside of Japan for more than 5 years total (confirmed by passport or intervi...
Prevnar 13 is a biologic vaccine developed by Pfizer for pneumococcal infections, a therapeutic area of infectious disease. It is also known as Prevenar 13. The product is studied in clinical trials that assess safety and immune response in healthy adult volunteers.
Prevnar 13 is intended for pneumococcal infections, which are bacterial infections caused by Streptococcus pneumoniae. Its clinical program has evaluated safety and immunogenicity in Japanese adults 18 to 49 years of age. The recorded trial enrolled 104 healthy volunteers in the United States.
Prevnar 13 is made by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the developer associated with the vaccine and its clinical program for pneumococcal infections.
Prevnar 13 is recorded at Phase 1 in its clinical development for pneumococcal infections. The single listed trial is a completed Phase 1 study, and no active trials are currently listed for this program.
Prevnar 13 has been studied in trial NCT03642847, titled Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age. The Phase 1 trial was completed, enrolled 104 participants, was randomized, double blind, and active controlled, and took place in the United States.
Yes, Prevnar 13 is also known as Prevenar 13, sometimes written Prevenar 13. The two names refer to the same Pfizer vaccine for pneumococcal infections, so readers searching either name are looking at the same product and clinical program.